Alemtuzumab for multiple sclerosis-Reference-Cited by-同舟云学术

Alemtuzumab for multiple sclerosis

Published:2023-06-05 Issue:6 Volume:2023 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Riera Rachel¹²³,Torloni Maria Regina⁴,Martimbianco Ana Luiza C¹²³⁵,Pacheco Rafael L¹²³⁶

Affiliation:

1. Cochrane Brazil Rio de Janeiro; Petrópolis Medical School; Petrópolis Brazil

2. Center of Health Technology Assessment; Hospital Sírio-Libanês; São Paulo Brazil

3. Núcleo de Ensino e Pesquisa em Saúde Baseada em Evidências e Avaliação de Tecnologias em Saúde (Nepsbeats); Universidade Federal de São Paulo; São Paulo Brazil

4. Cochrane Brazil; Centro de Estudos de Saúde Baseada em Evidências e Avaliação Tecnológica em Saúde; São Paulo Brazil

5. Postgraduate Program in Health and Environment; Universidade Metropolitana de Santos (UNIMES); Santos Brazil

6. Centro Universitário São Camilo; São Paulo Brazil

Publisher

Wiley

Subject

Pharmacology (medical)

Reference104 articles.

1. Alemtuzumab reverses pre-existing disability in relapsing-remitting multiple sclerosis patients independent of relapse history;Coles;Multiple Sclerosis,2009

2. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis;Coles;New England Journal of Medicine,2008

3. Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial;Coles;Neurology,2012

4. Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes;Coles;Lancet Neurology,2011

5. Alemtuzumab-related thyroid dysfunction in a phase 2 trial of patients with relapsing-remitting multiple sclerosis;Daniels;Journal of Clinical Endocrinology and Metabolism,2014

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluating the Therapeutic Potential of Ublituximab in the Treatment of MS: Design, Development and Place in Therapy;Drug Design, Development and Therapy;2024-07

2. The Role of Selected Interleukins in the Development and Progression of Multiple Sclerosis—A Systematic Review;International Journal of Molecular Sciences;2024-02-23

3. Selective Uptake of Macromolecules to the Brain in Microfluidics and Animal Models Using the HAVN1 Peptide as a Blood-Brain Barrier Modulator;Molecular Pharmaceutics;2024-02-23

4. In adults with relapsing-remitting multiple sclerosis (RR MS), how does alemtuzumab compare with other drug therapies?;Cochrane Clinical Answers;2023-08-08